Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $88.42 USD
Change Today -0.02 / -0.02%
Volume 966.9K
As of 8:04 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Snapshot

Open
$88.56
Previous Close
$88.44
Day High
$88.57
Day Low
$88.25
52 Week High
05/29/15 - $88.57
52 Week Low
10/15/14 - $46.56
Market Cap
15.3B
Average Volume 10 Days
1.1M
EPS TTM
$2.38
Shares Outstanding
172.8M
EX-Date
--
P/E TM
37.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for HOSPIRA INC (HSP)

hospira inc (HSP) Details

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of patients with autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a nonsteroidal anti-inflammatory drug analgesic. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

19,000 Employees
Last Reported Date: 02/12/15
Founded in 2003

hospira inc (HSP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $477.4K
Senior Vice President of Operations
Total Annual Compensation: $464.7K
President of Hospira Medical Devices
Total Annual Compensation: $512.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $550.5K
Compensation as of Fiscal Year 2014.

hospira inc (HSP) Key Developments

Hospira Inc., Q1 2015 Earnings Call, Apr 28, 2015

Hospira Inc., Q1 2015 Earnings Call, Apr 28, 2015

Hospira Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Hospira Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's net sales were $1,174.9 million compared with $1,050.8 million a year ago. The majority of the increase was due to continued strong net sales of Specialty Injectable Pharmaceuticals (SIP) in the United States. Income from operations was $133.4 million compared with $99.6 million a year ago. Adjusted income from operations was $247.2 million compared with $151.5 million a year ago. Income before income taxes was $121.9 million compared with $81.1 million a year ago. Net income was $75.6 million or $0.43 per diluted share compared with $67.9 million or $0.40 per diluted share a year ago. Adjusted net income was $170.1 million or $0.97 per diluted share compared with $101.7 million or $0.60 per diluted share a year ago. Net cash used in operating activities was $100.3 million compared with net cash provided by operating activities of $18.3 million a year ago. The decrease is primarily due to the upfront R&D milestone payment to Pfenex, higher employee incentive payments and higher investments in working capital. Capital expenditures (including instruments placed with or leased to customers) were $103.4 million compared with $95.1 million a year ago.

Hospira Inc. Presents at 4th Edition of Global Pharma Regulatory Summit 2015, Apr-24-2015 12:00 PM

Hospira Inc. Presents at 4th Edition of Global Pharma Regulatory Summit 2015, Apr-24-2015 12:00 PM. Venue: The Lalit, Sahar Airport Road, Mumbai - 400059, Maharashtra, India. Speakers: KS Babu, Head Regulatory.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $88.42 USD -0.02

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chugai Pharmaceutical Co Ltd ¥3,720 JPY -105.00
Endo International PLC $83.76 USD +0.82
Mallinckrodt PLC $129.44 USD -0.74
UCB SA €65.10 EUR +0.46
Zimmer Holdings Inc $114.09 USD +0.70
View Industry Companies
 

Industry Analysis

HSP

Industry Average

Valuation HSP Industry Range
Price/Earnings 44.7x
Price/Sales 3.3x
Price/Book 4.4x
Price/Cash Flow 44.8x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit www.hospira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.